雄激素受体及相关通道在激素非依赖性前列腺癌中的研究进展 |
| |
引用本文: | 徐威业,曹凤宏,景中民,荆文,李晓强.雄激素受体及相关通道在激素非依赖性前列腺癌中的研究进展[J].华北煤炭医学院学报,2010,12(5):635-637. |
| |
作者姓名: | 徐威业 曹凤宏 景中民 荆文 李晓强 |
| |
作者单位: | 华北煤炭医学院附属医院泌尿外科,河北唐山,063000 |
| |
摘 要: | 前列腺癌(PCA)是男性泌尿生殖系统的常见肿瘤,其发病率不但在欧美国家高居首位,而且在中国的发病率也呈显著上升趋势。早期,激素依赖性前列腺癌(HDPC)可以通过内分泌治疗达到缩小瘤体、降低血前列腺特异性抗原(PSA)的目的,但在治疗12—18个月后,80%前列腺癌患者逐渐演化为激素非依赖性前列腺癌(AIPC),导致患者最终死于激枣不敏感细胞的广泛转移。
|
关 键 词: | 前列腺癌 雄激素受体 通道 |
Research progress on androgen receptor and related paths in androgen independent prostate cancer |
| |
Abstract: |
Reid A,Attard G,Danila D,et al.A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreatedcastration-resistant prostate cancer (CRPC) patients (pts)J].J Clin Oncol,2009,27:5047
Ryan C,Efstathiou E,Smith M,et al.Phase II multicenter study of chemotherapy (chemo)-naive castration-resistantprostate cancer (CRPC) not exposed to ketoconazole(keto),treated with abiraterone acetate (AA) plus prednisoneJ].J Clin Oncol,2009,27:5046
Solit DB,Scher HI,Rosen N.Hsp90 as a therapeutic target in prostate cancerJ].Semin Oncol,2003,30:709
Morgan TM,Koreckij TD,Corey E.Targeted therapy for advanced prostate cancer:inhibition of the PI3K/Akt/ mTOR pathwayJ].Curr Cancer Drug Targets,2009,9:237
Wen Y,Hu MC,Makino K,et al.HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathwayJ].Cancer Res,2000,60:6841
>>更多... |
| |
Keywords: | |
本文献已被 CNKI 维普 万方数据 等数据库收录! |
|